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Background: Evidence suggests that earlier diagnosis and initiation of treatment
immediately after birth is critical for improved neurodevelopmental outcomes following
neonatal encephalopathy (NE). Current diagnostic tests are, however, mainly restricted
to clinical diagnosis with no molecular tests available. Purines including adenosine are
released during brain injury such as hypoxia and are also present in biofluids. Whether
blood purine changes can be used to diagnose NE has not been investigated to date.
Methods: Blood purines were measured in a mouse model of neonatal hypoxia
and infants with NE using a novel point-of-care diagnostic technology (SMARTChip)
based on the summated electrochemical detection of adenosine and adenosine
metabolites in the blood.
Results: Blood purine concentrations were ∼2–3-fold elevated following hypoxia in
mice [2.77 ± 0.48 µM (Control) vs. 7.57 ± 1.41 µM (post-hypoxia), p = 0.029]. Data in
infants with NE had a 2–3-fold elevation when compared to healthy controls [1.63 ± 0.47
µM (Control, N = 5) vs. 4.87 ± 0.92 µM (NE, N = 21), p = 0.0155]. ROC curve analysis
demonstrates a high sensitivity (81%) and specificity (80%) for our approach to identify
infants with NE. Moreover, blood purine concentrations were higher in infants with NE
and seizures [8.13 ± 3.23 µM (with seizures, N = 5) vs. 3.86 ± 0.56 µM (without
seizures, N = 16), p = 0.044].
Conclusion: Our data provides the proof-of-concept that measurement of blood purine
concentrations via SMARTChip technology may offer a low-volume bedside test to
support a rapid diagnosis of NE.
Keywords: neonatal encephalopathy, biomarker, purines, mouse models, clinical testing, seizures
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INTRODUCTION
Neonatal encephalopathy (NE), characterized by disturbed
neurological function in infants born ≥ 35 weeks of gestation,
is considered one of the most serious birth complications of full-
term infants accounting for 23% of infant mortality worldwide
(Millar et al., 2017). Infants with NE who survive infancy have
an increased risk of developing life-long neurological disorders
(e.g., learning disabilities, cerebral palsy, autism, epilepsy), which
adds significantly to the burden of NE (Shetty, 2015). The
combination of hypoxia and ischemia is commonly associated
with NE regardless of etiology (Aslam et al., 2019; Chalak et al.,
2019). Therapeutic hypothermia (TH) initiated within 6 h of birth
is the only standard-of-care treatment for moderate to severe NE
(Wassink et al., 2019). Despite this, long-term disabilities persist
in 50% of infants (Jacobs et al., 2013).
Evidence suggests that the key to better neurodevelopmental
outcomes following NE is earlier diagnosis and initiation
of TH immediately after birth (Thoresen et al., 2013).
Nevertheless, reliable and early diagnosis of NE remains a
clinical challenge. Current criteria for NE diagnosis such as
Apgar scores, need for delivery room intubation/resuscitation,
blood pH and neurological signs may sometimes be inaccurate,
inconsistent or misleading (Robertson and Perlman, 2006). Early
electroencephalogram (EEG) monitoring is useful to aid in
diagnosis but requires expertise and specialist equipment for
interpretation, which is not always available in the Neonatal
Intensive Care Unit (NICU), along with a high degree of
associated costs (Murray et al., 2016). There is, therefore, a
pressing need for the development of new, reliable diagnostic
and prognostic tests that will help accurately identify cases
of NE as soon as possible after birth to guide the initiation
of treatment and predict clinical outcomes. Several circulating
biomarkers are currently under investigation (Graham et al.,
2018). Among these, alterations in microRNA levels in umbilical
cord blood (O’Sullivan et al., 2019) and elevations of pro-
inflammatory cytokines in the blood (Chaparro-Huerta et al.,
2017; Omer et al., 2020; Sweetman et al., 2020) have shown
promising results. Detection techniques for these molecules do
not support a fast diagnosis, requiring sample preparation and
sophisticated equipment [e.g., enzyme-linked immunosorbent
assays (cytokines) and qPCR (microRNA)], potentially delaying
the diagnosis past the ideal therapeutic window of < 6 h post-
delivery. Thus, there remains a need for a molecular biomarker
of NE to enable a fast, affordable detection in an easy-to-use
point-of-care device.
Purinergic signaling, characterized as a complex regulatory
system governed by purine nucleotides such as ATP and
nucleosides, is involved in many critical processes of brain
development, such as cell proliferation and differentiation,
neuron-glia communication, neurotransmitter modulation and
inflammatory processes (Rodrigues et al., 2019). In animal
models of NE, inflammatory signaling is enhanced in conjunction
with upregulation of purine receptors, which can be targeted
therapeutically to reduce pathology (Rodriguez-Alvarez et al.,
2017; Menendez Mendez et al., 2020). Normally, purine signaling
molecules (e.g., ATP, adenosine) have relatively low extracellular
concentrations, and are also actively released following cellular
stress such as inflammation and hypoxia (Takahashi et al.,
2010; Thauerer et al., 2012). Blood purine levels (adenosine
and adenosine metabolites) have been shown to be increased in
the blood following stroke, ischemic brain injuries (Saugstad,
1975; Weigand et al., 1999; Laghi Pasini et al., 2000; Tian F.
et al., 2017; Dale et al., 2019) and, as shown more recently,
during epilepsy (Beamer et al., 2021). Increases in purine
nucleoside concentrations in biofluids post-hypoxia have been
reported previously in experimental models of neonatal hypoxia
suggesting diagnostic potential of purines for NE (Kuligowski
et al., 2017) and also in infants following hypoxia [e.g., increased
purines levels in cerebro-spinal fluid (CSF) (Harkness and Lund,
1983) and plasma (Saugstad, 1975; Buonocore et al., 2000)].
However, purines were not favorable as a diagnostic tool due to
their short half-life and by being difficult to measure. Recently
a novel enzyme-based amperometric biosensor (SMARTChip)
was demonstrated to detect a summed concentration of the
purine nucleoside adenosine and its metabolites, xanthine,
hypoxanthine and inosine (Dale and Frenguelli, 2009). Increases
in purine nucleoside concentration measured using this tool from
whole blood can offer a fast and reliable diagnostic tool for
ischemic stroke in adults (Dale et al., 2019), and can distinguish
epileptic patients from healthy individuals (Beamer et al., 2021).
Here, we investigated whether this approach was also useful in
the detection of NE. Using a mouse model of neonatal hypoxia
(Rodriguez-Alvarez et al., 2015) and measurements taken from
infants with NE, we investigated whether the SMARTChip
technology could reliably detect a spike in blood concentration
of purine nucleosides associated with NE.
MATERIALS AND METHODS
SMARTChip and Blood Purine
Measurement
The function of the SMARTChip (Sarissa Biomedical, Coventry,
United Kingdom) has previously been described in detail (Tian
D.S. et al., 2017; Dale et al., 2019; Beamer et al., 2021).
Briefly, a gel matrix is anchored to a gold-plated electrode and
contains a layer of three enzymes allowing for the detection
of adenosine, inosine, hypoxanthine and xanthine (Figure 1A).
Enzymes include: (1) Adenosine deaminase converting adenosine
into inosine, (2) Nucleoside phosphorylase converting inosine
into hypoxanthine and, (3) Xanthine oxidase converting
hypoxanthine into xanthine and H2O2 and urate and H2O2.
Amperometric measurement allows then for the detection and
quantification of electroreduction via peroxide produced by
Xanthine oxidase. This iterative sequence of enzymatic reactions
will lead to the formation of electroactive hydrogen peroxide
which is proportional to the summative concentration of all four
purines (adenosine and the intermediate substrates, xanthine,
hypoxanthine, and inosine) in the blood. Each SMARTChip
features two purine and two null sensors. Null sensors lack
sensitivity to purines, thereby acting as a control for any non-
specific interferences. All measurements are performed as the
difference between the two biosensors and the two null electrodes
giving a total of four reads for each sample: [(Purine sensor
1)—(Null sensor 1), (Purine sensor 1)—(Null sensor 2), (Purine
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sensor 2)—(Null sensor 1), (Purine sensor 2)—(Null sensor 2)].
The final result for each sample is the average of all four reads.
Before blood measurements, each SMARTChip is calibrated
in a solution containing 10 µM adenosine buffer solution
(adenosine in H2O), ensuring thereby minimal variability
between sensors. Accuracy and sensitivity of SMARTChips
to adenosine and adenosine down-stream purines (xanthine,
hypoxanthine and inosine) have been verified previously (Tian F.
et al., 2017; Beamer et al., 2021). Moreover, previous studies using
SMARTChip detection technology found very little interference
with purine measurement for ascorbate, acetaminophen and
urate (Beamer et al., 2021) which collectively provide more than
97% of the interfering signal for electrochemical measurements
(Albery et al., 1993). Measurements were taken from whole
blood taken from mice or infants, which was immediately
placed onto the gel-matrix-coated electrode and, results were
produced within minutes.
Neonatal Mouse Model of Hypoxic NE
All procedures were performed in accordance with the guidelines
of the European Communities Council Directives (86/609/EU
and 2010/63/EU) and were reviewed and approved by the
Research Ethics Committee of the Royal College of Surgeons in
Ireland (RCSI) (REC1302b) under license from the Department
of Health, Dublin, Ireland (B100/4524). Litters of male and
female C57BL/6 OlaHsd mice (Harlan, United Kingdom) were
kept with their dams in a barrier-controlled facility on a 12 h
light-dark cycle with access to food and water ad libitum. Hypoxia
was induced as described by exposing P7 mice (weight 4–6 g),
a developmental stage that roughly equates to the age of a term
infant (Semple et al., 2013), to a 95% N2/5% O2 premixed gas for
15 min. Normoxic controls were placed in the chamber at 21% O2
for the same period of time. Electrodes were implanted in both
experimental groups (normoxic controls and pups subjected to
hypoxia) and EEG recorded as previously described to confirm
the presence of seizures (Rodriguez-Alvarez et al., 2015). Hypoxic
conditions, 5% oxygen concentrations, were confirmed using
the Pico2-OEM optical oxygen meter (PyroScience, Germany).
A droplet of trunk blood was taken immediately following 15 min
of hypoxia to measure purine nucleoside concentrations using the
SMARTChip assay.
Newborn Patient Data and Clinical
Measurements
This study was approved by the Ethics Committee of the
Coombe Women and Infants University Hospital (CWIUH),
Dublin, Ireland, and Clinical Research Ethics Committee of the
Cork Teaching Hospitals (CUMH) [ECM 5(5) 04/07/17], Cork,
Ireland, both tertiary NICUs, and national referral centers for
TH. Families received verbal and documented information on
the study and written consent was obtained prior to recruitment.
We have previously recruited several distinct cohorts of infants
with NE and controls with criteria as described (O’Hare et al.,
2017; Sweetman et al., 2019). The severity of NE was classified
by Sarnat Staging (Sarnat and Sarnat, 1976). Infants with
congenital abnormalities or evidence of maternal substance
abuse were excluded. Whole blood sampling was performed
following informed parental consent. Sampling was performed
using aseptic technique via central and peripheral arterial lines
and via venous sampling at times of routine patient phlebotomy
and processed immediately. The volume taken was approved
by the Ethics committee, as a volume that would not affect the
infant’s hemodynamic status (approximately 20–50 µl). Neonatal
seizures were diagnosed (N = 5) using a combination of clinical
signs and amplitude integrated electroencephalography (aEEG)
or continuous EEG (cEEG). One infant died. Brain Magnetic
resonance imaging (MRI) was performed after completion of TH
on days 5–10 of life as part of routine clinical care. Our study
included 21 patients with NE and graded as follows: Sarnat score
I (N = 3); Sarnat score II (N = 15); Sarnat score III (N = 3). Blood
was taken as early as possible in order to test the potential of
stratification of infants according to severity via an arterial line,
from time of delivery until 4 days post-delivery from indwelling
arterial or venous umbilical catheters in neonates undergoing
TH. Infants with mild NE did not receive TH. Healthy term
aged-matched controls included asymptomatic infants (N = 5,
40% female) with an uneventful delivery, normal Apgar scores,
normal neonatal examinations, and without admission to the
NICU who underwent routine phlebotomy following informed
consent. Infants undergoing sepsis evaluations or receiving
phototherapy for jaundice were excluded. Blood was taken 2–
3 days post-delivery via peripheral venous sampling (details in
Supplementary Table 1).
Statistical Analysis
Statistical analysis of data was performed using Prism 8
(GraphPad) and STATVIEW software (SAS Institute). Data are
mean ± standard error of the mean (SEM). Unpaired Student’s
t-test was used for two-group comparison. Mann Whitney test
was performed to compare differences between two independent
groups where the dependent variable was either ordinal or
continuous, but not normally distributed. Receiver Operator
Characteristic (ROC) analysis was performed to investigate the
diagnostic ability of purine measurements for hypoxia in mouse
pups and infants with NE. Correlations between variables were
assessed using Pearson’s correlation coefficient. Significance was
accepted at p < 0.05.
RESULTS
Increased Blood Purine Concentrations
Following Hypoxia in Mice
Using a mouse model of neonatal hypoxia (Rodriguez-Alvarez
et al., 2015), we tested whether neonatal hypoxia leads to an
increase in blood purine concentrations. Blood purines were
measured via SMARTChip in whole blood in P7 mouse pups
subjected to hypoxia or normoxia (Control) conditions for
15 min at the time of re-oxygenation (Figure 1A). This analysis
provides a quantitative and summative analysis of adenosine and
the adenosine downstream purines inosine, hypoxanthine and
xanthine (Dale et al., 2019; Beamer et al., 2021). Hypoxia-induced
seizures were confirmed via cranial EEG recordings (Figure 1A).
Mouse pups subjected to hypoxia showed a ∼2-3 fold increase
in purine nucleosides when compared to normoxic control mice
Frontiers in Molecular Neuroscience | www.frontiersin.org 3 September 2021 | Volume 14 | Article 732199
fnmol-14-732199 September 2, 2021 Time: 12:49 # 4
Beamer et al. Purines and Neonatal Encephalopathy Diagnosis
FIGURE 1 | Increased blood purine concentrations following hypoxia in mice. (A) Schematic outlining functioning of SAMRTChip and neonatal hypoxia model in
mice. Blood purines are detected via an enzymatic cascade with enzymes entrapped within a layer on a Ruthenium Purple-coated gold electrode. This includes (A)
Adenosine deaminase which converts adenosine into inosine, (B) Nucleoside phosphorylase which converts inosine into hypoxanthine and (C) Xanthine oxidase
which converts hypoxanthine into xanthine and H2O2 and subsequently xanthine into urate and H2O2. Each SMARTchip consists of two purine biosensors and two
null biosensors. Final read is the difference between purine sensors subtracting the background measured via null sensors. P7 mice are subjected to 15 min of 5%
O2 experiencing hypoxia-induced seizures as detected via EEG recording. Blood purine concentrations were measured immediately following hypoxia using the
SMARTChip. (B) Graph showing increased purine concentrations in blood post-hypoxia in mouse pups. Whole trunk blood samples were collected between 0 and
10 min post-hypoxia (N = 10 control and 21 hypoxia), Unpaired Student’s t-test (t = 2,296; df = 29; p = 0.029). (C) ROC analysis shows blood purine concentration
had a 85.71% sensitivity, 80.00% specificity and AUC of 0.87 for identifying mice with hypoxia at a cut-off of 3.4 µM (N = 10 control and 21 hypoxia). *p < 0.05.
[2.77 ± 0.48 µM (Control, N = 10) vs. 7.57 ± 1.41 µM (post-
hypoxia, N = 21), p = 0.029] (Figure 1B). ROC curve analysis
demonstrated that changes in blood concentrations of purines
have a high level of sensitivity (85.71%) and specificity (80.00%)
to discriminate between control mice and mice subjected to
hypoxia at a cut-off of 3.4 µM with an area under the curve
(AUC) of 0.87 (Figure 1C). Thus, our data demonstrates that
hypoxia in mouse pups leads to changes in blood purine
levels and that we can detect these increases by using our
SMARTchip technology.
Increased Blood Purine Concentrations
Following NE in Infants
Clinical testing in infants (N = 26) (Figure 2A and Table 1)
revealed a ∼2–3-fold increase in blood concentration of purine
nucleosides following NE [1.63 ± 0.47 µM (Control, N = 5)
vs. 4.87 ± 0.92 µM (NE, N = 21), p = 0.0155; Figure 2B],
similar to our results obtained in mouse pups subjected to
hypoxia. ROC curve analysis showed that the SMARTChip assay
has a high level of sensitivity (80.95%) and specificity (80.00%)
for detecting NE in neonates at a cut-off of µM 1.99 with
an AUC of 0.84 (Figure 2C). Previous data, using the same
detection technology, has suggested seizures lead to increases
in blood purine concentrations in mice (Beamer et al., 2021).
Therefore, to test whether neonatal seizures increase purine
levels even further, infants with NE were grouped according to
the presence or absence of seizures. This analysis revealed that
the presence of neonatal seizures was associated with higher
blood concentrations of purines [3.86 ± 0.56 µM (NE without
seizures, N = 16) vs. 8.13 ± 3.23 µM (NE with seizures,
N = 5), p = 0.044; Figure 2D]. No correlation was, however,
found between blood purine concentrations and abnormal MRI
(p = 0.76) (Figure 2E) and Apgar score (p = 0.1419) (Figure 2F).
Also, no differences in blood purine levels were observed between
male and female infants under control conditions and post-NE
[Control: 1.69 ± 0.84 µM (male, N = 3) vs. 1.55 ± 0.31 µM
(female, N = 2) and NE: 5.2 ± 1.42 µM (male, N = 12) vs.
4.6 ± 1.1 µM (female, N = 9)] (Figure 2G) and the time of
blood sampling (p = 0.26) (Figure 2H). Taken together, our
results demonstrate the potential of our SMARTChip technology
in measuring blood purine levels as an informative clinical tool to
aid in the detection of NE.
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FIGURE 2 | Purine concentration changes in infants with neonatal encephalopathy. (A) Blood purine concentration was analyzed in whole blood via SMARTchip
1–4 days post-delivery. (B) Increased blood purine concentrations in infants with NE (N = 15) when compared to healthy controls (N = 5), Mann-Whitney test
(p = 0.0155). (C) ROC analysis shows blood purine concentration had a 80.95% sensitivity, 80.00% specificity and AUC of 0.84 for identifying infants with NE at a
cut-off of 1.99 µM. (D) Graph showing blood purine concentrations measured in infants with NE are higher in the presence of seizures (N = 16 (NE without seizures)
and 5 (NE with seizures), Unpaired Student’s t-test (t = 2.160; df = 19; p = 0.044). (E) Graph showing no correlation between purine concentrations when comparing
(Continued)
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FIGURE 2 | Continued
infants with normal MRI (N = 10) with infants with an abnormal MRI (N = 8) (p = 0.7572). (F) No correlation between purine concentrations and severity of NE
(N = 21, p = 0.1419). (G) No differences in purine concentrations between male and female infants under control conditions (male, N = 3; female, N = 2) (p = 0.9991)
and following NE (male, N = 12; female, N = 9; p = 0.8982). (H) No correlation between the time point of blood sampling and purine blood concentrations in infants
with NE (N = 26, p = 0.26). *p < 0.05.
DISCUSSION
This is the first demonstration of a simple method for the
detection of increased blood purine levels in infants with NE
at the bedside, which could provide a novel tool to support an
early and fast diagnosis of infants with NE. Currently, there is
no single gold standard biochemical biomarker to diagnose NE
nor prognosticate severity with accuracy in clinical use. Brain
MRI can help determine occurrence of injury, but is only possible
between 7 and 10 days after birth, i.e., outside the therapeutic
window. Circulating inflammation makers such as cytokines
(Chaparro-Huerta et al., 2017; Omer et al., 2020; Sweetman et al.,
2020) or microRNAs (O’Sullivan et al., 2019), have shown great
promise as novel diagnostic tools to support the identification
TABLE 1 | Clinical details of infants with corresponding blood purine
concentrations.






1 CWIUH 1 F 2 No 3.07
2 CWIUH 2 M 4 Yes 1.78
3 CWIUH 2 M 1 No 2.14
4 CWIUH 2 M 1 No 2.88
5 CWIUH 2 M 4 No 3.18
6 CWIUH 2 M 2 No 3.88
7 CWIUH 2 M 4 No 5.02
8 CWIUH 2 M 2 No 5.62
9 CWIUH 2 M 4 No 6.00
10 CWIUH 2 F 3 No 6.25
11 CWIUH 2 F 4 Yes 8.45
12 CWIUH 3 F 2 Yes 10.61
13 CWIUH 3 M 3 Yes 18.72
14 CUMH 1 F 1 No 2.12
15 CUMH 1 M 2 No 9.98
16 CUMH 2 M 2 No 1.35
17 CUMH 2 M 2 No 1.76
18 CUMH 2 F 1 No 2.44
19 CUMH 2 F 3 No 2.66
20 CUMH 2 F 2 No 3.41
21 CUMH 3 F 2 Yes 1.09
22 CWIUH Control M 2 − 1.05
23 CWIUH Control M 3 − 0.66
24 CWIUH Control M 2 − 3.35
25 CWIUH Control F 3 − 1.24
26 CWIUH Control F 3 − 1.86
CWIUH, Coombe Women and Infants University Hospital (Dublin, Ireland); CUMH,
Cork Teaching Hospitals (Cork, Ireland).
of infants with NE. Analyzing these markers requires, however,
sample preparation and, in some cases, equipment which is
not suited for use in the NICU. While it is well established
that hypoxia leads to changes of purines in biofluids (Saugstad,
1975; Harkness and Lund, 1983; Buonocore et al., 2000), their
instability in biofluids and the need for sophisticated equipment
[e.g., high-performance liquid chromatography (HPLC)] has
hamperd their progression as biomarkers into the clinic. Here, we
report increased blood purine levels in mice subjected to hypoxia
and in infants with NE using a new technology, SMARTChip.
This technique employs an electrochemical method for a
rapid detection of purines in whole, unprocessed blood via
a user-friendly diagnostic device (Dale et al., 2019), thereby
overcoming several limitations of current biomarkers under
investigation for NE.
Our results also show that blood purine levels increase further
in neonates with NE when seizures are present. The prognosis
for infants with NE and seizures is particularly poor, with
seizures leading to an increased rate of mortality and worsening
of clinical outcomes (Pisani and Spagnoli, 2016). EEG is an
excellent tool for assessing the severity of NE and for detecting
seizures but interpretation in neonates is an ongoing challenge
requiring specialized personnel and equipment (Boylan et al.,
2015). Our results suggest that analyzing blood purine levels may
not only support the detection of NE, but may also help in the
identification of infants at risk of neonatal seizures. This would
be in good agreement with a previous study showing increased
blood purine concentrations following provoked seizures in mice
(Beamer et al., 2021). It is tempting to speculate, therefore, that
the elevated blood purine levels in infants with NE and seizures
are a combination of both hypoxia- and seizure-driven increases
in purine release. It is, however, also possible that the additional
increases are simply the result of a more severe NE which is
usually accompanied by seizures (Pisani and Spagnoli, 2016).
Importantly, purine concentrations measured in this study
(low µM concentration range) are similar to previous studies
using the electrochemical detection approach (i.e., SMARTChip)
(Dale et al., 2019; Beamer et al., 2021) or studies using other
detection techniques (e.g., HPLC) (Harkness and Lund, 1983;
Zielinski et al., 2019). Moreover, blood purine concentrations
at baseline and blood purine increases under pathological
conditions (i.e., hypoxia in mice and NE in neonates) are similar
between species, demonstrating its translatability from animal
models to patients.
ATP is widely known to be released from cells throughout the
body under hypoxic stress, and is rapidly metabolized into purine
nucleosides. In fact, adenosine release allows tissue adaption
under ischemic/hypoxic conditions, via modulating vasodilation,
endothelial leakage and anti-inflammatory responses (Takahashi
et al., 2010). Adenosine levels increase rapidly with tissue
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hypoxia and inflammation (Rivkees and Wendler, 2011) and act
as neuromodulator conferring both protective and deleterious
effects via the activation of different adenosine receptors (e.g.,
A1, A2a, A2b, and A3) during several pathological conditions
(Levy et al., 2004; Rivkees and Wendler, 2011; Farr et al., 2020).
Whether increases of blood purines stem from the brain or
are due to peripheral release or whether the detected increases
represent a combination of both, remains to be established.
Due to the high purine quantities detected in the circulation
post-NE, contributions of brain-derived purines is, however,
unlikely under mild NE and may be restricted to severe
cases of NE with the associated brain injury. Two possible
peripheral sources of purine release during and following NE
include muscle tissue following increased muscle activity and
systemic inflammation. While muscle activity is an unlikely
source, as neonates with and without NE present similar
behaviors [e.g., neonatal seizures are often accompanied by
only subtle changes in behavior, further complicating their
diagnosis (Murray et al., 2016)], there is a substantial body
of evidence demonstrating altered immune responses (e.g.,
neutrophil activation) post-NE possibly contributing to increased
purine/adenosine concentrations (Barletta et al., 2012; Karmakar
et al., 2016; Wang and Chen, 2018; O’Dea et al., 2020; Kelly et al.,
2021). Of note, similar to increased blood purines in infants with
seizures, inflammation markers are also highly associated with
seizures (Zareen et al., 2020). Nevertheless, the source of blood
purine changes should be addressed in future studies.
Because our approach provides a combined measurement
of adenosine and the adenosine breakdown products inosine,
hypoxanthine and xanthine, we are unable to determine which
of these purines contributes to the observed increase in blood
purine concentrations during NE. However, due to the longer
half-live (minutes) of inosine and hypoxanthine when compared
to adenosine (seconds), these are most likely adenosine down-
stream purines (Wung and Howell, 1984; Moser et al., 1989).
In line with this, previous studies have shown increased
hypoxanthine and xanthine in the blood following hypoxia in
neonates (Saugstad, 1975; Harkness et al., 1983; Buonocore et al.,
2000; Plank et al., 2011).
It is, however, important to keep in mind that changes in blood
purine concentrations are not unique to hypoxia and NE and
have been previously reported following traumatic brain injury,
cerebral and cardiac ischemia, endotoxemia, and seizures among
others (Weigand et al., 1999; Laghi Pasini et al., 2000; Bell et al.,
2001; Ramakers et al., 2011; Farthing et al., 2015; Dale et al.,
2019; Beamer et al., 2021). Blood adenosine concentrations have
also been found increased in umbilical cord blood in infants
following vaginal deliveries when compared to elective cesarean
sections (Irestedt et al., 1989) and in premature newborns with
white matter brain injury (Panfoli et al., 2016, 2018). Thus,
elevations in blood purines/adenosine levels may represent a
global phenomenon in response to any type of brain injury, rather
than being specific to hypoxia or NE. Nevertheless, a biomarker
for NE would most likely not be used as a stand-alone test and
would be evaluated within a clinical context in combination
with other measures. Moreover, while diagnostic tools for the
identification of NE are available, there is a pressing need to
stratify infants by severity using biomarkers. This would identify
neonates with mild NE, which do not meet diagnostic criteria
for TH but who have been shown to have adverse long-term
neurodevelopment outcomes if untreated (Finder et al., 2020).
Although one of the main limitations of the study is the
small sample size, infants were enrolled at two hospital sites
for validation. Even though blood purine concentrations seem
to correlate with seizures, infant numbers will have to be
significantly increased to validate these results. Finally, purine
measurements should be taken at different time-points during
longitudinal sampling and purine concentrations correlated
to response to treatment and clinical outcomes and other
confounding factors such as duration of labor, vaginal vs.
cesarean birth and elective vs. emergency delivery. Moreover,
although sampling was carried out as early as possible within the
first 4 days post-delivery, next steps should confirm higher blood
purine levels post-NE immediately after birth.
In summary, this study demonstrates that blood purine
nucleoside concentrations are increased following NE and have
potential to be a novel bedside test based on blood purine
changes. This may provide another tool for clinicians for a timely
diagnosis of NE, critical for improving clinical outcomes.
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